TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05330455
Drug: Bepirovirsen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bepirovirsen will be administered
Study: NCT05768919
Drug: Treatment Period 1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Agent: LipoCurc Premedication/Precautions: Dexamethasone 4mg IV, Diphenhydramine 25 mg IV - Dose: per treatment assignment Route: IV over approximately 3 hours Schedule: Weekly: Weeks 1,2, 3,4,5,6 Cycle length: 6 weeks~Agent: TMZ Premedications/Precautions No food 2 hr before and after dosing Antiemetic (eg, ondansetron, prochlorperazine) 30 minutes before dosing Stool softener PRN. Dose: 75 mg/m2 Route: Oral Schedule: Daily during term of RT Cycle Length: 6 weeks~Agent: Radiotherapy Premedications/Precautions: n/a Dose: 2 Gy Route: External beam therapy Schedule: Monday-Friday Cycle Length 6 weeks
Study: NCT05768919
Drug: Treatment Period 3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Agent: LipoCurc Premedication/Precautions: Dexamethasone 4 mg IV Diphenhydramine 25 mg IV Dose: Per treatment assignment Route: IV over approximately 3 hours Schedule: Weekly: Adjuvant Cycles 11-34 Weeks 1, 2, 3, 4 of each cycle Cycle Length: 4 weeks~Agent: TMZ Premedication/Precautions: No food 2 hr before and after dosing. Antiemetic (eg, ondansetron, prochlorperazine) 30 minutes before dosing Stool softener prn Dose: 150-200 mg/m2 (Cycles 1-6) Route: Oral Schedule: Daily Cycle Length: 4 weeks
Study: NCT05548738
Drug: medthylprednisolone
Normalized name: Methylprednisolone
DrugBank: Methylprednisolone (DB00959)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: a type of steroids injected in epidural space
Study: NCT05170828
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: pre-transplant conditioning treatment
Study: NCT05170828
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: post-transplant treatment for GVHD
Study: NCT05593250
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: subcutaneous ,placebo
Study: NCT05677113
Drug: QBECO
Normalized name: Quinolinate Benzodiazepine Ester Compound
Approvals — FDA: no, EMA: no, PMDA: no
Description: QBECO is a site specific immunomodulator (SSI) designed to promote innate immune responses in the gastrointestinal tract and related organs, including the liver. QBECO will be administered according to the following regimen: 0.1mL self-administered subcutaneous injections every 2 days for 11-120 days preoperatively, and 41 days postoperatively.
Study: NCT00499720
Drug: Aztreonam Lysine for Inhalation
Normalized name: aztreonam Inhalation Solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: 75 mg three times a day via inhalation for 28 days followed by 28 days off drug.
Study: NCT05677113
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo will be prepared in the same way as the IP. Placebo will be administered according to the following regimen: 0.1mL self-administered subcutaneous injections every 2 days for 11-120 days preoperatively, and 41 days postoperatively.
Study: NCT05563038
Drug: Standard Medication Management
Approvals — FDA: no, EMA: no, PMDA: no
Description: Medications such as: gabapentin, duloxetine and Lyrica are all FDA approved for treatment of neuropathic pain, particularly that caused by diabetes.
Study: NCT05180240
Drug: CardiolRx
Normalized name: CARDIOTEX RX TAB
Approvals — FDA: no, EMA: no, PMDA: no
Description: Eligible patients will be randomized to receive CardiolRx or placebo. Intervention will be administered orally (via syringe) with food twice daily.
Study: NCT05642442
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matching placebo capsule(s) administered every day (QD) orally. Titration may proceed at a rate of 1 matching placebo capsule per day every 7 days as required for optimal efficacy and tolerability up to a maximum number of 3 matching placebo capsules per day.
Study: NCT05201248
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: IV Injection
Study: NCT05201248
Drug: Doxorubicin
Normalized name: Doxorubicin
DrugBank: Doxorubicin (DB00997)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: IV Infusion
Study: NCT05401578
Drug: Placebo (0.9% NaCl)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 ml 0.9 % saline solution s.c. Patients will be randomized at visit 2 = Baseline to either placebo (1 ml 0.9 % saline solution s.c.) or treatment with 1 ml 150 mg canakinumab solution s.c. in a 1:1 manner.
Study: NCT06535789
Drug: Inhaled Technosphere Insulin
Normalized name: insulin, regular, human Inhalation Powder [Afrezza]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients will receive TI (Afrezza) to be compared to RAA following a breakfast meal
Study: NCT05958342
Drug: saline placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: saline placebo volume matched to prehospital or in hospital phase
Study: NCT03953703
Drug: Levocarnitine
Normalized name: Levocarnitine
DrugBank: Levocarnitine (DB00583)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Levocarnitine 1000 mg twice per day for 6 weeks
Study: NCT03953703
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo 1000 mg twice per day for 6 weeks
Study: NCT06042920
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Specified dose on specified days
Study: NCT04907851
Drug: RXC004
Approvals — FDA: no, EMA: no, PMDA: no
Description: RXC004 will be administered orally, 2 mg QD; Dose Formulation: 0.5 mg or 1 mg capsules.
Study: NCT04907851
Drug: RXC004
Approvals — FDA: no, EMA: no, PMDA: no
Description: RXC004 will be administered orally, 2 mg QD (Cohort 1, Module 2) and 1 mg QD (Cohort 2, Module 2); Dose Formulation: 0.5 mg or 1 mg capsules.
Study: NCT04907851
Drug: RXC004
Approvals — FDA: no, EMA: no, PMDA: no
Description: RXC004 will be administered orally, 1.5 mg QD; Dose Formulation: 0.5 mg or 1 mg capsules.
Study: NCT05869903
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered orally.
Study: NCT04895761
Drug: Cyclophosphamide 50mg
Normalized name: CYCLOPHOSPHAMIDE 50MG TAB
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: oral chemotherapy used in the neoadjuvant setting for Arm C only
Study: NCT05868057
Drug: SHR7280 tablets
Approvals — FDA: no, EMA: no, PMDA: no
Description: SHR7280 tablets 1 time
Study: NCT04716114
Drug: SKLB1028
Approvals — FDA: no, EMA: no, PMDA: no
Description: SKLB1028 will be administered by oral capsules, 150 mg twice daily (BID).
Study: NCT06016387
Drug: Capecitabine
Normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Capecitabine is a tumour-activated antineoplastic agent (antimetabolite). The molecular formula for capecitabine is C15H22FN3O6 and has a molecular weight of 359.35 g/mol.
Study: NCT04482712
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administration of investigational drug placebo for up to 4 weeks while hospitalized
Study: NCT06379399
Drug: Trifluridine/Tipiracil
Normalized name: TRIFLURIDINE/TIPIRACIL
Approvals — FDA: no, EMA: no, PMDA: no
Description: Phase I:~1. 6 patients (male and female) will be enrolled to evaluate safety. Patients will receive Trifluridine/Tipiracil at a dose of 35mg/m2 (maximum single dose of 80 mg). Patients will be followed up for Dose-Limiting Toxicities (DLTs) (2 Cycles, Day 1-Day 28). If ≤2 patients experience DLTs (2 Cycles, Day 1-Day 28), the study will proceed to Phase II with a dose of 35mg/m2. If ≥3 patients experience DLTs (2 Cycles, Day 1-Day 28), the study will proceed to Phase II with a dose of 30mg/m2.~2. Based on the results of the 35mg/m2 dose group, 6 patients (male and female) will be enrolled in the 30mg/m2 dose group to evaluate safety. Patients will be followed up for DLTs (2 Cycles, Day 1-Day 28). If ≤2 patients experience DLTs (1 Cycle, Day 1-Day 28), the study will proceed with a dose of 30mg/m2 in Phase II.~Phase II:~Trifluridine/Tipiracil: po, twice daily from Day 1-5, every two weeks, based on the recommended dose from Phase I;
Study: NCT05549219
Drug: GLM101
Approvals — FDA: no, EMA: no, PMDA: no
Description: GLM101 IV Infusion
Study: NCT04940325
Drug: DS-1062a
Normalized name: Uretron DS
Approvals — FDA: no, EMA: no, PMDA: no
Description: First infusion for 90 minutes and then infusion duration can be decreased to 30 minutes if participant didn't experience infusion related reactions (IRR)
Study: NCT06308198
Drug: AGN-151586
Normalized name: VITEX AGNUS-CASTUS WHOLE
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intramuscular Injections
Study: NCT06308198
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intramuscular Injections
Study: NCT05345171
Drug: Oral Corticosteroids
Normalized name: CORTICOSTEROIDS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants who receive DTX301 solution will receive oral corticosteroids.
Study: NCT05345171
Drug: Placebo for oral corticosteroids
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants who receive Placebo will receive placebo corticosteroids to maintain the study blind
Study: NCT05085574
Drug: Celecoxib
Normalized name: Celecoxib
DrugBank: Celecoxib (DB00482)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 400 mg (initial dose), then 200 mg capsule, BID for 5 days
Study: NCT05085574
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: tablet, QID for 14 days; capsule, BID for 5 days
Study: NCT05312008
Drug: Intranasal placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Initial volume 1 ml; 2 booster volumes of 0.6 mls each, spaced about 1 hour apart
Study: NCT04706975
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral Placebo administered twice daily
Study: NCT05067283
Drug: MK-1084
Normalized name: vitamin MK 7
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral dose
Study: NCT05067283
Drug: leucovorin
Normalized name: Leucovorin
DrugBank: Leucovorin (DB00650)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Per label
Study: NCT05626751
Drug: HZN-825
Approvals — FDA: no, EMA: no, PMDA: no
Description: HZN-825 will be administered BID for 52 weeks
Study: NCT05420727
Drug: Ga-68-PSMA-11 PET/CT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ga-68-PSMA-11 PET/CT imaging
Study: NCT04878406
Drug: NNC0480-0389
Approvals — FDA: no, EMA: no, PMDA: no
Description: A single dose of subcutaneous NNC0480-0389. The study will last for a maximum of 72 days.
Study: NCT04878406
Drug: Placebo (NNC0480-0389)
Approvals — FDA: no, EMA: no, PMDA: no
Description: A single dose of subcutaneous placebo (NNC0480-0389) The study will last for a maximum of 72 days.
Study: NCT04878406
Drug: Placebo (Semaglutide)
Approvals — FDA: no, EMA: no, PMDA: no
Description: A single dose of subcutaneous placebo (semaglutide) The study will last for a maximum of 72 days.
Study: NCT05577871
Drug: normal saline
Normalized name: Normal Saline Flush
Approvals — FDA: no, EMA: no, PMDA: no
Description: infusion of normal saline during the off pump coronary artery bypass grafting surgery
Study: NCT06383767
Drug: ESG401
Approvals — FDA: no, EMA: no, PMDA: no
Description: IV infusion on day 1,8, and 15 of each 28 day cycle
Study: NCT05158491
Drug: JK-1201I
Approvals — FDA: no, EMA: no, PMDA: no
Description: JK-1201I will be given every 3 weeks, maximum of 4 treatment cycle.
Study: NCT05267821
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: See information in arm/group descriptions
Study: NCT05983367
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo
Study: NCT06265051
Drug: Saline placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: After the completion of endovascular treatment and successful recanalization (mTICI 2b/3), the patients were randomly assigned to the experimental group. Saline placebo was administered in the same manner as tirofiban group. Standard medical treatment was administered after the surgery.
Study: NCT05983367
Drug: FOLFIRI regimen
Normalized name: Anacin Aspirin Regimen Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: FOLFIRI regimen (irinotecan 180 mg/m2 over 90 minutes concurrently with folinic acid 400 mg/m2 over 2 hours, and then 5-FU 2400 mg/m2 over 46 hours on Days 1 and 15 of each 28-day cycle)
Study: NCT06036914
Drug: Bumetanide
Normalized name: Bumetanide
DrugBank: Bumetanide (DB00887)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Bumetanide will be administered via intravenous (IV) infusion at a dose of 12.5 mg two times a day (BID) for 2 doses total within 24 hours.
Study: NCT04380831
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Undergo HSCT
Study: NCT05802056
Drug: Fluorouracil
Normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given IV
Study: NCT05802056
Drug: Leucovorin Calcium
Normalized name: Leucovorin Calcium
DrugBank: Leucovorin (DB00650)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given IV
Study: NCT06546436
Drug: CARC-101C
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subjects enrolled in the project will received a one-dose injection of CARC-101C
Study: NCT06383390
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered SC
Study: NCT06290141
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pharmaceutical form: Solution Route of administration: IV solution
Study: NCT06290141
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pharmaceutical form: Solution Route of administration: SC solution
Study: NCT06290141
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pharmaceutical form: Placebo to match intravenous immunoglobulin IVIg for IV infusio Route of administration: IV solution
Study: NCT05832931
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants will receive intravenous (IV) placebo, containing no active drug, three times per week for 27 weeks.
Study: NCT05832931
Drug: Open-Label Extension PLS240
Normalized name: BOTTLE OPENER
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants will receive intravenous (IV) PLS240 three times per week for a maximum of 26 weeks.
Study: NCT04920682
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.9% saline solution (SF) when TOF = 3 and when TOF (T4 / T1)\> 0.4
Study: NCT04808245
Drug: Tecentriq 1200 MG in 20 ML Injection
Normalized name: Tecentriq 1200 MG in 20 ML Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: One vial of Tecentriq® (1200 mg) will be administered as an intravenous (i.v.) infusion over 60 minutes every 3 weeks starting 4 weeks after radiotherapy. If the first infusion is tolerated, all subsequent infusions will be delivered over 30 minutes.
Study: NCT04370145
Drug: Sulperazon
Approvals — FDA: no, EMA: no, PMDA: no
Description: moderate cholangitis patients were treated with these drugs for 7days,unless the patients were cured or must be changed the therapeutic.
Study: NCT06206733
Drug: ASKB589
Approvals — FDA: no, EMA: no, PMDA: no
Description: ASKB589 will be administered as a minimum 3-hour IV infusion
Study: NCT06206733
Drug: Capecitabine
Normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Capecitabine will be administered orally twice daily (bid).
Study: NCT06206733
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo will be administered as a minimum 3-hour IV infusion
Study: NCT05177133
Drug: Capecitabine
Normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: PO Capecitabine
Study: NCT06506591
Drug: WD-890
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Administered P.O.
Study: NCT06506591
Drug: WD-890 Tablets Placebo
Normalized name: PLACEBO TAB
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered P.O.
Study: NCT05251129
Drug: Pravastatin 40 Mg Oral Tablet
Normalized name: pravastatin 40 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lower intensity statin
Study: NCT04777331
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prasinezumab placebo will be administered to participants.
Study: NCT06243770
Drug: mRNA-0184
Normalized name: SARS-CoV-2 (COVID-19) vaccine, mRNA-1273 Injectable Suspension [Spikevax]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous infusion
Study: NCT05546853
Drug: Calcium levofolinate
Normalized name: calcium levofolinate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Calcium levofolinate will be administreted at the first day of each cycle (CnD1) of 14 days as an IV infusion at 100 mg/m²
Study: NCT05546853
Drug: 5 FU
Normalized name: i5 Functional Food Nutritional Powder for Suspension (Vanilla Delight)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 FU will be administreted at the first day of each cycle (CnD1) of 14 days as an IV infusion at 2400 mg/m2 as a continuous intravenous infusion over 46 hours.
Study: NCT05835895
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: intra-articular injection
Study: NCT04881838
Drug: P regimen
Normalized name: Natural Acne Solutions 3 Step Regimen KIT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dexamethasone 5 mg/m2 Days 1 and 2; 10mg/m2 Day 3 to 5; Cyclophosphamide 200 mg/m2 Days 1 and 2 Intrathecal therapy Day 1
Study: NCT04881838
Drug: Course A2 + Vin
Normalized name: PROCYANIDIN A2
Approvals — FDA: no, EMA: no, PMDA: no
Description: vinorelbine 25 mg/m2, Day 1 Dexamethasone 10 mg/m2 Days 1 to 5; Methotrexate 3g/m2, 3-hour infusion Day 1; Etoposide 100mg/m2, Days 4 to 5; Ifosfamide 800 mg/m2, Days 1 to 5; Cytarabine 150 mg/m2, q12h Days 4 to 5;
Study: NCT04881838
Drug: Course B3 +Vin
Normalized name: VITAMIN B3
Approvals — FDA: no, EMA: no, PMDA: no
Description: vinorelbine 25 mg/m2, Day 1; Dexamethasone 10 mg/m2 Days 1 to 5; Methotrexate 3g/m2, 3-hour infusion Day 1; Cyclophosphamide 200 mg/m2, Days 1 to 5; Doxorubicin 25 mg/m2, Days 4 to 5;
Study: NCT04881838
Drug: Maintenance therapy
Normalized name: Dental Resources Perio Maintenance Rinse
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vinorelbine 25 mg/m2 IV, weekly for 3 consecutive weeks followed by 1-week rest. Totally 80 cycles.
Study: NCT06349057
Drug: reducing anticholinergic burden
Normalized name: Iron, reduced
DrugBank: Iron (DB01592)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: In the intraoperative and postoperative periods instead of drugs with high anticholinergic burden; drugs with low burden will be preferred.
Study: NCT05187624
Drug: RO7428731
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants will receive RO7428731 as described.
Study: NCT06104839
Drug: NXC736
Approvals — FDA: no, EMA: no, PMDA: no
Description: oral administration
Study: NCT06104839
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: oral administration
Study: NCT06020235
Drug: 5% Nu-3 gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: The gel is called Nu-3 which is either applied once per day or twice per day to the infected ulcer.
Study: NCT06020235
Drug: 10% Nu-3 gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: The gel is called Nu-3 which is either applied once per day or twice per day to the infected ulcer.
Study: NCT06020235
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo gel is either applied once per day or twice per day to the infected ulcer.
Study: NCT06647888
Drug: Envlo Tablet
Normalized name: ENVIO 30 Day Daily Essentials Duo KIT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Envlo Tab. 0.3mg
Study: NCT06647888
Drug: Envlomet SR Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Envlomet SR Tablet 0.3/ Metformin1,000mg
Study: NCT06546397
Drug: 17β-estradiol/dydrogesterone tablets
Approvals — FDA: no, EMA: no, PMDA: no
Description: The medication group began taking 17β-estradiol/dydrogesterone tablets orally for 28 days starting from the first day after induced abortion surgery (taking 2mg of 17β-estradiol orally once a day for the first 14 days, and then taking 2mg of 17β-estradiol + 10mg of dydrogesterone tablets orally once a day for the next 14 days). The blank control group did not take any medication.
Study: NCT05726916
Drug: Soliris®
Approvals — FDA: no, EMA: no, PMDA: no
Description: Eculizumab IV administration (900mg/w during 4w then 1200 mg at w5 and 1200mg/2w for 8w) + Blood pressure control with renin angiotensin system blockers
Study: NCT05726916
Drug: Renin angiotensin system blockers
Approvals — FDA: no, EMA: no, PMDA: no
Description: Blood pressure control with renin angiotensin system blockers
Study: NCT06528262
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients hospitalized at Severance Hospital for atrial fibrillation catheter ablation, or those who had the procedure within the last three months, will be randomly assigned to receive either 0.3 mg of enavogliflozin once daily or a placebo for 360±30 days
Study: NCT06648434
Drug: mFOLFIRINOX
Approvals — FDA: no, EMA: no, PMDA: no
Description: Includes oxaliplatin, irinotecan, leucovorin, and 5-FU.
Study: NCT05361421
Drug: Intensive targeting group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intensive lipid lowering therapy with LDL-cholesterol goal of \<55mg/dL. Atorvastatin 5, 10, 20, 40, and 80mg are allowed to use and ezetimibe or PCSK-9 inhibitor may be considered in patients who could not achieve target LDL-cholesterol level even with the maximum dose of study drugs (atorvastatin 80mg) by the discretion of the investigator.
Study: NCT05361421
Drug: Conventional therapy group
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Only moderate intensity statin therapy (atorvastatin 5, 10, and 20mg ) are allowed. Ezetimibe or PCSK-9 inhibitor is not allowed to use.
Study: NCT05299658
Drug: CNMAu8
Approvals — FDA: no, EMA: no, PMDA: no
Description: CNM-Au8 is an aqueous suspension of clean surfaced faceted nanocrystals consisting of gold atoms self-organized into crystals of various geometrical shapes (hexagonal bi-pyramid, pentagonal bi-pyramid, tetrahedron, decahedron, planar spheroids). Those choosing to participate in the OLE period will orally receive 30 mg of CNM-Au8, once daily.
Study: NCT06416800
Drug: Rosuvastatin
Normalized name: Rosuvastatin
DrugBank: Rosuvastatin (DB01098)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Oral; Tablet
Study: NCT06481735
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Intravenous cyclophosphamide 500\~1000 mg/m\^2/day on days -5, -4, and -3.
Study: NCT03845751
Drug: HIFU hemi-ablation combined with ADT.
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hemi-ablation of the cancer-harbouring prostatic lobe will be carried out using HIFU energy. Short-term 3-month ADT will be administered concomitantly. Short-term ADT is administered as a single subcutaneous injection of 3-month depot of 22.5 mg of leuprolide acetate (luteinizing hormone-releasing hormone \[LHRH\] agonist). The ADT protocol starts within 1 month prior to the scheduled HIFU session